Beisol Pharma Neerijse: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
Beisol Pharma Neerijse
Largest movements
- Receivables within one year -€6,587
down €6,587 (-20.7%), from €31,815 to €25,228
of which Trade receivables: -€9,090
- Trade debts -€5,250
no longer reported in 2026 (was €5,250)
- Other debts -€3,841
down €3,841 (-2.7%), from €143,653 to €139,812
- Profit (loss) carried forward +€2,911
up €2,911 (+5.1%), from -€57,539 to -€54,628
- Gross operating margin -€6,304
down €6,304 (-65.1%), from €9,691 to €3,387
- Purchases and services +€6,304
up €6,304 (+74.3%), from €8,489 to €14,793
From the 2025 result to the 2026 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Derived from the 2025 and 2026 balance sheets and the 2026 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2025 | 2026 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €102,180 | €95,422 | -€6,758 | -6.6% |
| Current assets | 29/58 | €102,180 | €95,422 | -€6,758 | -6.6% |
| Stocks and contracts in progress | 3 | €70,160 | €70,160 | = | 0.0% |
| Stocks | 30/36 | €70,160 | €70,160 | = | 0.0% |
| Amounts receivable within one year | 40/41 | €31,815 | €25,228 | -€6,587 | -20.7% |
| Trade receivables | 40 | €31,815 | €22,725 | -€9,090 | -28.6% |
| Other amounts receivable | 41 | - | €2,503 | +€2,503 | |
| Cash at bank and in hand | 54/58 | €205 | €34 | -€171 | -83.4% |
| Total equity and liabilities | 10/49 | €102,180 | €95,422 | -€6,758 | -6.6% |
| Equity | 10/15 | -€47,301 | -€44,390 | +€2,911 | +6.2% |
| Contributions | 10/11 | €6,200 | €6,200 | = | 0.0% |
| Capital | 10 | €6,200 | €6,200 | = | 0.0% |
| Issued capital | 100 | €18,600 | €18,600 | = | 0.0% |
| Uncalled capital | 101 | €12,400 | €12,400 | = | 0.0% |
| Reserves | 13 | €4,038 | €4,038 | = | 0.0% |
| Non-distributable reserves | 130/1 | €202 | €202 | = | 0.0% |
| Legal reserve | 130 | €202 | €202 | = | 0.0% |
| Distributable reserves | 133 | €3,836 | €3,836 | = | 0.0% |
| Profit (loss) carried forward | 14 | -€57,539 | -€54,628 | +€2,911 | +5.1% |
| Amounts payable | 17/49 | €149,481 | €139,812 | -€9,669 | -6.5% |
| Amounts payable within one year | 42/48 | €149,481 | €139,812 | -€9,669 | -6.5% |
| Trade debts | 44 | €5,250 | - | -€5,250 | |
| Suppliers | 440/4 | €5,250 | - | -€5,250 | |
| Taxes, remuneration and social security | 45 | €578 | - | -€578 | |
| Taxes | 450/3 | €578 | - | -€578 | |
| Other amounts payable | 47/48 | €143,653 | €139,812 | -€3,841 | -2.7% |
| Turnover | 70 | €18,180 | €18,180 | = | 0.0% |
| Goods, raw materials, services and sundry goods | 60/61 | €8,489 | €14,793 | +€6,304 | +74.3% |
| Other operating charges | 640/8 | €387 | €411 | +€24 | +6.2% |
| Gross operating margin | 9900 | €9,691 | €3,387 | -€6,304 | -65.1% |
| Operating profit (loss) | 9901 | €9,304 | €2,976 | -€6,328 | -68.0% |
| Financial charges | 65/66B | €30 | €65 | +€35 | +117% |
| Recurring financial charges | 65 | €30 | €65 | +€35 | +117% |
| Profit (loss) for the period before taxes | 9903 | €9,274 | €2,911 | -€6,363 | -68.6% |
| Profit (loss) for the period | 9904 | €9,274 | €2,911 | -€6,363 | -68.6% |
| Profit (loss) for the period to be appropriated | 9905 | €9,274 | €2,911 | -€6,363 | -68.6% |
Source: filed annual accounts (NBB), financial years ended 31 March 2025 and 31 March 2026. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 28 October 2026 via checked.be.